SEC Form 4 · accession 0001209191-17-022143

Aclaris Therapeutics, Inc. · ACRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Mar 17, 2017

Accepted (ET)

Mar 21, 2017 · 8:43 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001557746

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 17, 2017	M	6,702	$0.41	A	6,702	D
Common Stock	Mar 17, 2017	M	592	$1.52	A	7,294	D
Common Stock	Mar 17, 2017	M	311	$0.72	A	7,605	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock option (right to buy)^F1	$0.41	Mar 17, 2017	M	6,702	D	—	Jan 28, 2024	Common Stock	6,702	1,993	D
Stock option (right to buy)^F2	$1.52	Mar 17, 2017	M	592	D	—	Dec 7, 2024	Common Stock	592	462	D
Stock option (right to buy)^F3	$0.72	Mar 17, 2017	M	311	D	—	Aug 12, 2024	Common Stock	311	171	D

F125% of the shares underlying this option vested on January 29, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.
F225% of the shares underlying this option vested on December 8, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.
F325% of the shares underlying this option vested on August 13, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.